文献速递垂体与肾上腺疾病

Relacorilant治疗库欣综合征的疗效与安全性:GRACE 3期随机撤药研究

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study.
PubMed 文献 · Lancet Diabetes Endocrinol · 2026-02-20

GRACE研究为多中心3期双盲安慰剂对照随机撤药试验,纳入内源性高皮质醇血症伴高血压或高血糖的成人患者。开放标签relacorilant治疗22周后,应答者随机继续relacorilant或安慰剂12周。继续relacorilant者高血压失控比例显著低于安慰剂,安全性可接受。

要点

  • Relacorilant为选择性糖皮质激素受体调节剂,可竞争性抑制皮质醇活性。
  • 未观察到肾上腺功能不全、药物性低钾血症或QT间期延长等安全性事件。

核心结论

  • Relacorilant治疗组患者比安慰剂组更可能维持高血压控制。
  • 结果支持考虑将relacorilant作为减少内源性高皮质醇血症有害影响的治疗选择。

研究设计与样本

  • 多中心、3期、双盲、安慰剂对照、随机撤药研究,在11个国家77个中心开展。
  • 纳入18-80岁内源性高皮质醇血症伴高血压、高血糖或两者兼有的成人,且至少有两个高皮质醇血症临床征象或症状。
  • 开放标签阶段口服relacorilant每日一次,从100 mg递增至400 mg,治疗22周。
  • 达到应答标准者按1:1随机分配至继续relacorilant 400 mg(或最高耐受剂量)或安慰剂,治疗12周。
  • 共筛查404例,入组152例,95例完成开放标签阶段,62例随机分配(relacorilant组30例,安慰剂组32例)。

主要发现

  • 随机撤药期安全性人群中,relacorilant组与安慰剂组常见不良事件包括背痛(17% vs 19%)、痤疮(10% vs 0)、关节痛(10% vs 9%)、滑囊炎(10% vs 0)、头痛(10% vs 13%)、失眠(0 vs 13%)。
  • 未发生过度糖皮质激素受体拮抗、肾上腺功能不全、与子宫内膜增生相关的阴道出血、药物性低钾血症或药物性QT间期延长。

关键数值与推荐

  • 主要结局为随机撤药期第12周时失去高血压应答的患者比例,在意向治疗人群中比较relacorilant与安慰剂。
  • 缺失随机撤药第12周数据视为失去应答。
  • relacorilant组30例中21例符合高血压应答标准,安慰剂组32例中22例符合。

临床怎么用

  • 对于内源性高皮质醇血症伴高血压的患者,relacorilant可能有助于维持高血压控制。
  • 治疗期间需监测不良事件,但本研究未观察到肾上腺功能不全、低钾血症或QT间期延长等特定安全性事件。

局限性

  • 随机撤药阶段样本量较小(relacorilant组30例,安慰剂组32例)。
  • 研究仅评估了12周随机撤药期的结局,长期疗效与安全性未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relacorilant is a selective glucocorticoid receptor modulator designed to reduce excess cortisol activity by competing with cortisol for glucocorticoid receptor binding, mitigating the clinical manifestations of endogenous hypercortisolism (Cushing's syndrome). The aim of this study was to assess the efficacy and safety of relacorilant in adults with endogenous hypercortisolism. METHODS: This multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study enrolled adults with endogenous hypercortisolism and hypertension, hyperglycaemia, or both and was conducted at 77 study centres across 11 countries. Key inclusion criteria included being aged 18-80 years with at least two clinical signs or symptoms of hypercortisolism. In the open-label phase, patients received oral, once-daily relacorilant (escalation from 100 mg up to 400 mg) for 22 weeks. Patients who met response criteria were randomly assigned (1:1) by the interactive web response system to continue relacorilant 400 mg (or highest tolerated dose) or placebo for 12 weeks in the randomised-withdrawal phase. Participants and investigators were masked to treatment assignment. The primary outcome was the proportion of patients who lost hypertension response during the randomised-withdrawal phase compared between relacorilant and placebo at week 12. As per protocol, this outcome was assessed in all participants who received at least one dose of study drug in the study period (intention-to-treat population). Missing randomised-withdrawal week 12 values were considered a loss of response. Safety was assessed in all enrolled patients who received at least one dose of study drug in that period. This study is registered with ClinicalTrials.gov, NCT03697109. FINDINGS: Between Oct 16, 2018, and April 15, 2024, 404 patients were screened, 152 were enrolled, and 95 completed the open-label relacorilant phase. 62 patients met response criteria and were randomly assigned to relacorilant (30 total participants [21 met hypertension response criteria]) or placebo (32 total participants [22 met hypertension response criteria]). In the 30 participants in the relacorilant group, the mean age was 46·6 years (SD 11·0), 22 (73%) were female, and eight (27%) were male. In the 32 participants in the placebo group, the mean age was 48·8 years (SD 14·4), 26 (81%) were female, and six (19%) were male. During the randomised-withdrawal phase, significantly more patients with baseline hypertension who were randomly assigned to placebo lost hypertension control compared with those who continued relacorilant (proportion difference 34%; odds ratio 0·17 [95% CI 0·04-0·77]; p=0·022). In the randomised-withdrawal phase safety population, the most common adverse events in the 30 participants given relacorilant and the 32 participants given placebo were back pain (5 [17%] vs 6 [19%]), acne (3 [10%] vs 0), arthralgia (3 [10%] vs 3 [9%]), bursitis (3 [10%] vs 0), headache (3 [10%] vs 4 [13%]), and insomnia (0 vs 4 [13%]). There were no cases of excessive glucocorticoid receptor antagonism, adrenal insufficiency, vaginal bleeding associated with endometrial hypertrophy, drug-induced hypokalaemia, or drug-induced QT interval prolongation. INTERPRETATION: Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic option to reduce the harmful and debilitating effects of endogenous hypercortisolism. FUNDING: Corcept Therapeutics.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Pivonello R, Arnaldi G, Auchus RJ, et al. Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study. Lancet Diabetes Endocrinol. 2026. PMID: 41730814. doi:10.1016/S2213-8587(25)00362-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。